Biodesix (NASDAQ:BDSX) Stock Breaks Below 200 Day Moving Average – Here’s Why

Biodesix, Inc. (NASDAQ:BDSX) crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $18.90 and traded as low as $7.96. Biodesix shares last traded at $8.53, with a volume of 1,586,239 shares trading hands.

Trending Headlines about Biodesix

Here are the key news stories impacting Biodesix this week:

• Neutral Sentiment: Biodesix plans to end 2026 with approximately 115 sales representatives, an effort to expand its commercial reach. Article
• Negative Sentiment: Third-quarter revenue was $24.04 million, below analysts’ estimate of $27.49 million. Biodesix reported a loss of $0.75 per share; one cited consensus was $0.75, while Zacks reported a $0.74 estimate. Article
• Negative Sentiment: For 2026, the company forecast revenue of $101 million to $103 million, below the $111.7 million analyst consensus—signaling a weaker outlook than investors had expected. Article
• Negative Sentiment: Biodesix disclosed the departure of Chief Commercial Officer Ki…; the leadership change may add uncertainty as the company works to grow sales. Article
• Negative Sentiment: Following the sharp decline, Johnson Fistel said it had opened an investigation into whether Biodesix or its officers made misleading statements or failed to disclose material information. This is an investigation, not a finding of wrongdoing. Article

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Weiss Ratings upgraded Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 8th. HC Wainwright reiterated a “buy” rating on shares of Biodesix in a research note on Thursday, October 22nd. TD Cowen reiterated a “buy” rating and issued a $40.00 target price (up from $30.00) on shares of Biodesix in a research note on Tuesday, October 13th. Finally, Canaccord Genuity Group increased their target price on shares of Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $36.25.

Biodesix Price Performance

The business has a 50 day moving average price of $25.53 and a two-hundred day moving average price of $18.90. The stock has a market cap of $89.99 million, a PE ratio of -3.09 and a beta of 0.65. The company has a debt-to-equity ratio of 5.12, a quick ratio of 2.85 and a current ratio of 2.85.

Biodesix (NASDAQ:BDSX) last released its earnings results on Thursday, November 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.75). The company had revenue of $24.04 million during the quarter, compared to analyst estimates of $27.49 million. Biodesix had a negative return on equity of 513.78% and a negative net margin of 25.74%. Research analysts expect that Biodesix, Inc. will post -2.68 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Biodesix news, Director Jack Schuler acquired 15,000 shares of Biodesix stock in a transaction on Wednesday, August 12th. The stock was purchased at an average price of $24.47 per share, for a total transaction of $367,050.00. Following the purchase, the director directly owned 555,810 shares of the company’s stock, valued at $13,600,670.70. This trade represents a 2.77% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders acquired a total of 42,600 shares of company stock valued at $1,033,062 over the last 90 days. 23.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Biodesix

A number of hedge funds have recently made changes to their positions in the business. Allworth Financial LP purchased a new position in shares of Biodesix in the 2nd quarter worth about $112,000. Walleye Capital LLC purchased a new stake in Biodesix during the first quarter worth about $157,000. Renaissance Technologies LLC purchased a new stake in Biodesix during the first quarter worth about $173,000. Cetera Investment Advisers raised its position in Biodesix by 20.0% in the first quarter. Cetera Investment Advisers now owns 12,000 shares of the company’s stock worth $174,000 after acquiring an additional 2,000 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in Biodesix in the second quarter valued at about $354,000. 20.96% of the stock is currently owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions.

Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.